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1. Introduction 
Worldwide around 7 million people suffer myocardial infarctions per year according to 
White et al. (2008). Around one third of these patients having acute myocardial infarction 
die within the first hour of having symptoms usually due to fatal arrhythmia. 
Characteristic ST segment elevation in the 12 lead electrocardiogram (ECG) accompanied 
by clinical symptoms of chest pain provide the most rapid way to diagnose those patients 
who should receive thrombolysis to help dissolve thrombus and restore blood flow. In 
fact, since the early 1980s, thombolysis has been the cornerstone of treatment for patients 
having ST segment elevation myocardial infarctions (STEMI) by improving outcomes and 
preserving left ventricular function. There are in fact many large randomised clinical trials 
which support early thrombolysis and these can be found in the Fibrinolytic Therapy 
Trialists’ (FTT) Collaborative Group publication from 1994. This document reinforces the 
importance of early reperfusion with 30 lives per 10000 being saved by thrombolysis 
given within 6 hours of presentation and 20 lives per 1000 saved if initiation is between 6 
and 12 hours.  
2. Pathophysiology of myocardial infarction  
Acute myocardial infarction which is commonly known as a heart attack is the interruption 
of blood supply and therefore oxygen to heart muscle thereby potentially causing cell death 
or necrosis. This is usually due to the occlusion of the coronary artery lumen by clot called 
thrombus. This thrombus is formed by the rupture of unstable arteriosclerotic plaque which 
consists of white blood cells (mainly macrophages) which engulf lipids to form foam cells 
covered with a fibrous cap in the arterial wall. The plaque can rupture as a result of many 
factors including the mechanical shear stress from blood flow and flexion and tension of the 
fibrous causing it to be injured and thinned. Rupture exposes adhesion molecules in the sub-
endothelium which form thrombus when exposed to flowing blood. This allows primary 
haemostasis to occur, resulting in platelet adhesion, platelet activation and aggregation 
forming thrombus. Thrombolytic drugs break down this thrombus thereby restoring blood 
flow and preventing further damage to myocardium. It is therefore obvious to see that the 
sooner myocardial infarction is diagnosed and the earlier thrombolysis can be given the 
greater the myocardial salvage. 
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3. Clinical indications 
The indications for thrombolysis in myocardial infarction rely on eliciting a history of 
typical clinical symptoms (mainly but not exclusively chest pain) and diagnosing 
characteristic changes in the 12-lead electrocardiogram (ECG) which is a non-invasive 
means of recording the electrical activity of the heart over seconds using transthoracic 
electrodes. The prompt recognition of the characteristic symptoms and ECG changes are 
required to institute rapid reperfusion therapy through thrombolysis. 
The main clinical symptom of acute myocardial infarction is central or left-sided chest pain 
which can be described as dull, squeezing or tightness. This is called angina pectoris. The 
pain most commonly radiates to the left arm but can radiate to the neck, jaw, epigastrium, 
back and the right side of the chest. The management of myocardial infarction also requires 
prompt relief of the ischaemic pain with oxygen, opiates and sublingual or intravenous 
nitrates which act through vasodilatation. Other symptoms are shortness of breath from left 
ventricular dysfunction and resultant pulmonary oedema due to myocardial ischaemia. The 
remaining symptoms are due to surges of catecholamines from sympathetic overdrive such 
as palpitations, nausea, vomiting, light-headedness, weakness, anxiety and excessive 
sweating termed diaphoresis. Loss of consciousness may also occur and is usually due to 
arrhythmia as a consequence of ischaemia or cerebral hypoperfusion due to poor left 
ventricular output and cardiogenic shock. Notably women tend to report more atypical 
symptoms and so when making a diagnosis clinicians should bare this in mind. To 
complicate matters further around one quarter of patients suffering an acute myocardial 
infarction do not have any symptoms at all. These ‘silent’ myocardial infarctions most 
commonly occur in the elderly and diabetic patients. This can cause problems when 
selecting out patients that are suitable for thrombolysis as the clinician would have to rely 
on the ECG criterion and any other relevant history that is available at that time.  
Other scenarios where a history may be difficult to obtain are patients that are acutely 
breathless from pulmonary oedema or those that have been successfully resuscitated or are 
being resuscitated from cardiac arrest. In these situations if the ECG shows characteristic 
changes and the bleeding risk from chest compressions is felt to be low then an experienced 
clinician can make the decision to proceed with thrombolysis. In cardiac arrests with 
refractory ventricular fibrillation and a prior history of chest pain or ischaemic heart disease 
then also in these cases a decision may be taken to give thrombolysis.  
4. Electrocardiogram criterion 
The ECG criterion for thrombolysis are well validated and need to be met before initiation of 
therapy. As mentioned earlier the ECG is a recording of electrical activity as it spreads 
through the heart muscle. The ECG can be daunting in its interpretation  and in itself a 
massive topic but here we focus specifically on the parts of the ECG that are relevant for 
diagnosing acute myocardial infarction suitable  for thrombolysis. 
Ventricular depolarisation and contraction are represented on the ECG by a waveform 
termed the QRS complex which is later followed by a smaller deflection termed the T wave 
which constitutes ventricular repolarisation and relaxation. In fact, repolarisation begins 
with the ST segment which connects the QRS complex to the T wave. The beginning of the 
ST segment is termed the J point.  
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Fig. 1. An electrocardiogram showing ST elevation in leads III and AVF. 
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The criterion for thrombolysis refer to the QRS complex and ST segments and are as follows: 
1. 1mm of ST segment elevation from the J point in at least 2 contiguous limb leads (I, 
II,III, AVF and AVL) 
2. 2mm of ST segment elevation from the J point in at least 2 contiguous chest leads (any 
two of V1 to V6) 
New onset left bundle branch block. This is recognised as characteristic deflections of the 
QRS complex and an increased width of greater than 120 milliseconds which is 3 small 
squares on the ECG when the recording speed is set to the usual 25mm/second. 
The various limb leads and chest leads pick up electrical signals by literally overlying and 
'pointing' towards various parts of the heart. Therefore   ECG changes in certain leads 
represent ischaemia affecting certain territories or areas of heart muscle. ECG changes in 
leads I and AVR represent ischaemia in the anterior wall of the left ventricle while II, III, and 
aVF represent the inferior aspect of the heart. The V leads or chest leads show if the anterior-
septal area is affected (V1-V4) and the late V leads signify infarction of the lateral wall of the 
ventricle. Leads I and AVL also represent the lateral territory of the heart. The criterion 
requires that these changes are in at least two contiguous leads because this is more likely to 
represent a significant area or 'territory' of myocardium. ST segment changes in a single lead 
are more likely to be due to other causes the most likely being normal variant due to an 
earlier repolarisation of the myocardium. Clinicians also need to bear in mind alternative 
diagnoses which could present with ST elevation by ECG. Acute pericarditis, which is a 
usually benign condition of pericardial inflammation, can present with ST elevation but 
typically the ST segment has a saddle-shaped appearance. The clinical symptoms may also 
mimic myocardial infarction but the classical description is of pain is different in that it is 
sharp and stabbing which varies with respiration and is also positional. Clinically the 
patient may also have an audible rub on auscultation using a stethoscope. This is a scratchy 
noise caused by the inflamed layers of pericardium rubbing against each other. The other 
condition in which ST elevation may be present is when the patient has an outpouching of 
the left ventricle termed an aneurysm. Again the ECG can have a more characteristic 
Clinicians should keep the possibility of these alternative diagnoses at the forefront of their 
minds to avoid misdiagnosis and therefore inappropriate administration of thrombolysis. 
Other ECG changes that accompany ST elevation may also be present and aid the diagnosis 
of acute ST elevation myocardial infarction. The T waves may become hyperacute and lose 
their normal concavity. There may also be the presence of a pathological Q wave at the start 
of the QRS complex which is represented by a negative deflection of at least 1 small square 
on the ECG (40 milliseconds). This is said to represent infarcted non-viable myocardium. 
The other common abnormality which can accompany ST elevation is ST depression in 
reciprocal leads. Essentially, this means that leads looking at the opposite aspect of the heart 
show a mirror image of the leads showing ST elevation. 
5. Contraindications for thrombolysis 
Contraindications to thrombolysis in myocardial infarction can be separated into absolute 
and relative ones. Absolute contraindications are suspected dissecting aortic aneurysm, 
ischaemic stroke within 3 months (except if acute and within 3 hours of symptom onset 
when it is a treatment), intracranial neoplasm or arterio-venous malformation, active 
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bleeding diathesis, uncontrolled hypertension (systolic>180mmHg or diastolic >100mmHg), 
significant closed-head trauma or facial trauma within 3 months.  
Rigorous cardiopulmonary resuscitation or compressions of greater than 10 minutes 
duration is a relative contraindication to thrombolysis. Other scenarios which require 
precaution include active peptic ulceration, therapeutic anticoagulation with warfarin 
therapy, active menstruation, pregnancy, recent streptococcal infection of less than five 
days, controlled severe hypertension, haemorrhagic or diabetic retinopathy and invasive or 
surgical procedure in the preceding three weeks.  
6. Evidence base for thrombolysis and alternative strategies 
Initially, streptokinase infusion produced conflicting results until the (GISSI) trial in 1986, 
which validated streptokinase as an effective therapy and established a fixed regime for its 
use in acute myocardial infarction. As mentioned earlier the evidence supporting 
thrombolysis as opposed to not giving thrombolysis is outlined in the Fibrinolytic Therapy 
Trialists’ (FTT) Collaborative Group publication from 1994. This combined the data from 9 
trials and included a total of 58,600 patients. Here, the obvious survival advantage of 
thrombolysis in ST segment elevation in myocardial infarction and left bundle branch block 
was established. However, excess deaths were noted in the elderly and those thrombolysed 
after 12 hours of symptom onset.  Most notably, it was clearly seen that the earlier 
thrombolysis was given the greater the benefit. The reason being that the earlier reperfusion 
is achieved the smaller the infarct size and the greater the myocardial salvage, which in turn 
has a significant impact on morbidity and mortality. This has led to targets for thrombolysis 
to be initiated within 20 to 30 minutes of arrival at hospital (‘‘door to needle’’ time) and 
within 60 minutes of calling for help (‘‘call to needle’’ time) across the UK and in Europe.  
Primary percutaneous coronary intervention (PPCI) has evolved as an alternative 
emergency treatment for patients with STEMI. This is an invasive keyhole procedure which 
involves the passing of thin catheters from the femoral or radial arteries in to the aorta and 
then in to the openings of the coronary arteries to act as a conduit for various specialized 
equipment that can be used to treat the acute thrombus. The equipment used for this 
purpose are primarily clot extraction catheters termed extraction catheters, inflatable 
balloons and metal stents which act as a scaffold for keeping the arteries open.  Although 
the number of patients receiving this treatment is steadily increasing because of the 
potential benefits, not all hospitals have the facilities to provide this therapy and so most 
patients in Europe still receive thrombolysis as initial management.  
Once thrombolysis was established as a mode of treatment it was initially given in hospital 
by clinicians but with the extensive data that early thrombolysis yielded better outcomes 
there was a move towards pre-hospital thrombolysis (PHT). This involved emergency 
services giving thrombolysis at the scene on arrival to the patient.  
Meta-analyses of RCTs show that PHT is superior to in-hospital thrombolysis (IHT) as it 
saves on average 30 minutes to 1 hour from the time between calling for medical help and 
initiation of thrombolysis. The time benefit is even more apparent where ambulance 
transport times are long. For this reason IHT is only reserved for those places that that do 
not offer PHT or PPCI. When PPCI is not available or offered around the clock then PHT 
becomes the treatment modality of choice to ensure the maximal myocardial salvage. 
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Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction 
(CAPTIM) compared PHT directly against PPCI.  This showed that if thrombolysis was 
administered within 2 hours of symptom onset mortality data at 30 days strongly favoured 
this treatment over PPCI. However, after 2 hours the trend of outcomes reversed and PPCI 
became the treatment of choice. This was mirrored in the PRAGUE-2 trial which showed the 
benefits of IHT up to 3 hours.  
In contrast to this the Primary Coronary Angioplasty vs. Thrombolysis (PCAT)-2 Trialists 
Collaborative Group meta-analysis looked at IHT versus an invasive strategy and showed 
that PPCI was superior to thrombolysis with lower mortality rates and risk of re-infarction. 
In the USA, guidelines favour the data on PHT over PPCI but also focus on the time factor 
with regards to reperfusion. They recommend that PHT should be given within 30 minutes 
after the arrival of emergency services at the scene and if this is not available and the patient 
is transferred to a hospital without PPCI facility then IHT should be given within 30 minutes 
of arrival at the centre (this is termed to door-to-needle time). If PPCI is offered in the 
hospital then actual disruption of the acute thrombus in the coronary artery should take 
place within 90 minutes (termed door-to-balloon time).  European guidelines differ in that 
they prefer PPCI as the primary mode for reperfusion but with the several caveats. They 
stipulate that the procedure should be performed by a skilled operator in a high volume 
centre (operator performing more than 75 PCIs a year and the centre performing more than 
200 PCIs) within 120 minutes of the first medical contact or within 90 minutes in patients 
receiving medical help within 2 hours from the onset of symptoms. If PPCI is not available 
then thrombolysis should be given within 3 hours of symptom onset with preference given 
to PHT over IHT. 
7. Rescue PCI, routine PCI and facilitated PCI 
When thrombolysis fails then rescue PCI should be considered. In the REACT trial patients 
that had not been successfully treated by thrombolysis after 90 minutes from initiating 
therapy (signified by less than 50% resolution of ST segment resolution by ECG) were 
randomized between conservative management, repeat thrombolysis and rescue PCI. This 
trial showed a clear benefit of the latter in all outcome data including 6 month mortality. 
Rescue PCI should therefore be offered to all patients within 12 hours of symptom onset. 
This may therefore involve patient transfer to a centre that offers a PCI service if not 
available at the hospital where the patient was thrombolysed or where they were taken after 
PHT. The exact definition of failed thrombolysis is controversial but the absence of chest 
pain is considered as misleading as opiates, analgesics and vasodilators may contribute to 
this. Generally accepted markers are taken as ST segment resolution of less than 50-70% and 
the time taken to assess whether thrombolysis has taken effect is between 45 and 90 minutes. 
All patients should receive PCI subsequent to this, ideally within a period of 24 hours, but a 
benefit is even seen up to 30 days as evidenced by the CAPTIM trial. GRACIA-1, CARESS-
in-AMI and the WEST trials all looked at PCI within a quicker time frame after thrombolysis 
and the overall results showed that this was comparable to PPCI outcomes when the post-
thrombolysis PCI was performed within 24 hours. The very recent TRANSFER-AMI trial 
reinforced the benefits of a pharmaco-invasive strategy which compared PCI at 6 hours after 
thrombolysis with ‘standard treatment’ which involved thrombolysis with delayed 
angiography and PCI (after 24 hours). There was a statistically significant reduction in the 
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primary endpoint of combined incidence of death, reinfarction, recurrent ischemia, new or 
worsening heart failure, or cardiogenic shock at 30 days for the pharmaco-invasive strategy 
(11% in the pharmaco-invasive arm vs. 17.2% in the standard treatment arm). There was 
also less recurrent ischaemia (0.2% vs. 2.1%) and reinfarction (3.4% vs. 5.7%) in the 
pharmaco-invasive strategy and fewer congestive heart failure (3.0% vs. 5.6%). On the other 
hand, there were more deaths and more patients experiencing cardiogenic shock in the 
pharmaco-invasive arm but these differences were not statistically significant. There were 
significantly more minor bleeding episodes in the combined strategy arm when compared 
to standard treatment but there was no difference in major bleeding.  It is important to note 
that this pharmaco-invasive strategy is very different to thrombolysis followed by immediate 
PCI. This is called facilitated PCI and in fact has failed to shows clinical benefit and may in 
fact be harmful. The reason for this being that if PCI is performed too early then the 
thrombolytic administered is still active causing increased bleeding risk as well as resulting 
in more acute stent thrombosis (the potentially catastrophic blocking of a stent by thrombus 
within 24 hours of it being deployed) which is caused by the increased platelet activation 
and aggregation which accompanies thrombolytics. 
The ideal setting for PHT in the USA involves an experienced physician being available to 
interpret the ECG by either being part of the Emergency Medical service team on the 
ambulance or being available to review a copy of a transmitted ECG. This has proved harder 
to achieve in Europe where more frequently, trained paramedics decide on whether the 
ECG meets criterion. Some UK studies have shown that this is safe and sometimes even 
better than the physician-assisted model due technological issues when transmitting the 
ECG or failure of mobile phones when trying to communicate to doctors from remote areas. 
However, in contrast a study in Finland has shown that having physicians on site for PHT is 
superior to paramedics alone. A checklist of contraindications should also be gone through 
prior to administration to ensure that the patient is not placed at increased risk of 
catastrophic bleeding. Therefore, this can also be used as a means of identifying those 
patients that are more suitable for PPCI. 
8. Adjunctive therapies for thrombolysis 
Aspirin is well established as an adjunctive therapy to thrombolysis and it is recommended 
that 150 to 325mg of chewable aspirin be given to the patient with thrombolysis. 
Clopidogrel is an oral, thienopyridine class antiplatelet agent which when given at a dose of 
300 mg also provides prognostic benefit. The COMMIT-CCS-2 and CLARITY-TIMI 28 trials 
provided this evidence for adding clopidogrel to aspirin in patients undergoing fibrinolytic 
therapy. 
It is recommended that unfractionated heparin, an intravenous anticoagulant is given 
intravenously with all of the thrombolytics to enhance clot dissolution and decrease the risk 
of re-occlusion. In vitro studies and animal models show discordant results regarding 
concomitant administration of heparin with thrombolysis suggesting that it may enhance, 
inhibit or have no effect. Hsia J et al.(1990) have shown that thrombolysis achieves faster 
lysis with greater vessel patency in combination with heparin (between 7 and 24 hours a 
patent vessel was found in 88% of those receiveing thrombolysis with heparin and aspirin 
vs. 52% in those treated with thrombolysis and aspirin alone). Unfortunately this does not 
translate into clinical outcome with a meta-analysis of the six trials by Muhaffey KW et al. 
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(1996) showing that there were similar rates of mortality and re-infarction before discharge. 
Despite this the general consensus from expert opinion is that heparin is beneficial in 
preventing re-occlusion and that it should be given as a bolus with all thrombolytics other 
than Streptokinase and then be given as a continuous IV infusion. With the advent of low 
molecular weight heparins (LMWHs) which only need once or twice daily subcutaneous 
administration without regular blood monitoring the continuous IV infusion of 
unfractionated heparin has been superseded by these newer anticoagulants. In fact there is 
evidence that the LMWH, Enoxaparin, appears superior to UFH in the EXTRACT-TIMI 25 
trial when given during thrombolysis. In fact, patients under the age of 75 years can be 
given a 30 mg intravenous bolus followed by the subcutaneous dose every 12 hours. In 
practice this intravenous preparation LMWH is less widely available and UFH is more 
commonly given. 
9. Thrombolytics used in clinical practice 
9.1 Streptokinase 
This was the first thrombolytic used in the treatment of STEMI and remains the cheapest 
and most commonly used. Two large trials were pivotal in demonstrating the efficacy of 
Streptokinase as a thrombolytic in myocardial infarction which reduces mortality when 
compared against placebo. The first of these was the GISSI trial mentioned earlier, published 
in 1986 and included 11,712 patients. This trial showed that at 21 days the mortality for 
patients treated with Streptokinase was 10.7% vs 13% for the placebo group which 
represented a statistically significant absolute reduction of 2.3% (risk ratio 0.81; 95% 
confidence ratio [CI] 0.72 to 0.9). The second trial, ISIS-2 trial included 17,187 patients and 
was published 2 years after GISSI in 1988. In this study, vascular mortality at 5 weeks was 
9.2% in the streptokinase group and 12% in those treated with placebo which represented a 
statistically significant absolute reduction of 2.8%. Streptokinase is administered as an IV 
infusion over 1 hour. Streptokinase has a few side-effects which are namely low blood 
pressure termed hypotension, infrequent allergic reactions and sometimes although not 
commonly, anaphylaxis. Patients treated with streptokinase develop anti-streptococcal 
antibodies, which is why patients should only ever receive this drug once in a lifetime. 
9.2 Alteplase 
A meta-analysis of eight trials which compared alteplase with streptokinase found that there 
was no significant difference between the two drugs in terms of mortality up to 35 days. 
However, re-infarction rates were found to be in favour of alteplase but this was offset by a 
doubling in the risk of haemorrhagic stroke (odds ratio 2.13; 95% CI 1.04 to 4.36). In contrast 
to this, streptokinase was associated with a statistically significant higher risk of major 
bleeds than alteplase. However, the definitions of major bleeding varied between the trials 
and so it is difficult to judge the clinical significance of these findings.  
9.3 Alteplase 
Alteplase which is also known as recombinant human tissue plasminogen activator or rtPA 
can be delivered in a standard or accelerated regimen. The accelerated regimen, which is 
much more commonly used especially in PHT because of its ease of administration as it is 
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delivered by an initial IV bolus injection. This is followed by only two IV infusions at 30 
minutes and 60 minutes. The GUSTO-I trial was the only study in the meta-analysis 
mentioned above which looked at the more commonly used accelerated regimen rather than 
the standard regimen. This trial which included over 40000 patients was also the only trial to 
demonstrate superiority over different thrombolytics with an absolute reduction in 
mortality at 30 days of 1.0% (6.3% versus 7.3%; 95% CI 0.4% to 1.6%) in favour of accelerated 
alteplase when compared to streptokinase. However, this benefit was balanced by a 
statistically significantly higher incidence of haemorrhagic stroke (odds ratio 1.42; 95% CI 
1.05 to 1.91). Using a combined outcome measure of mortality and disabling stroke, there 
was in fact a statistically significant absolute advantage of streptokinase over alteplase of 
0.9%;p = 0.006). Interestingly, statistically significant rates of moderate bleeding or worse 
were lower in the alteplase group. Alteplase also fared better with regards to the common 
side effects experienced by streptokinase namely causing less allergic reactions, anaphylaxis, 
and sustained hypotension and these were also statistically significantly lower. Despite this 
a further meta-analysis of nine trials comparing standard alteplase with streptokinase, 
including the findings of GUSTO-I (i.e. accelerated alteplase), found no significant difference 
between the two drugs in terms of mortality up to 35 days (odds ratio 0.94; 95% CI 0.85 to 
1.04). 
9.4 Reteplase 
This is the third most commonly used thrombolytic and one of the easiest to administer as it 
only involves two IV boluses administered 30 minutes apart. The INJECT study involving 
nearly 6000 patients compared reteplase to streptokinase. This study found an absolute 
difference in 35 day mortality of 0.5% (95% CI –1.98% to 0.96%) in favour of reteplase but 
this was not deemed as statistically significant. Similarly to alteplase, when a combined 
outcome measure using overall effects on mortality and disabling stroke is applied to the 
trial data then reteplase may in fact be inferior to streptokinase, as the trial also found a 
statistically significantly lower risk of haemorrhagic stroke in the streptokinase group (odds 
ratio 2.1; 95% CI 1.02 to 4.31). However, the trial also found that the  in the reteplase group 
the rates of heart failure (23.6% vs 26.3%, p<0.05) and allergic reactions (1.1% vs 1.8%, 
p<0.05) were significantly lower. In one small study of 324 patients (RAPID-2), reteplase 
was compared to alteplase and this found that better vessel patency was achieved when 
coronary angiography was the endpoint. Subsequent to this the large GUSTO-III trial 
involving 15,059 was designed to test the clinical superiority of reteplase over accelerated 
alteplase. However, GUSTO-III found no statistically significant difference between the two 
drugs, in terms of survival or adverse effects but at 30 days mortality was 7.5% in the 
reteplase group and 7.2% in the accelerated alteplase group giving an absolute risk 
reduction of 0.23% in favour of accelerated alteplase (95% CI–1.10% to 0.66%). Therefore, 
reteplase cannot be considered as equivalent to accelerated alteplase. 
9.5 Tenectaplase 
This is the easiest of the thrombolytics to administer and only involves a single bolus. 
ASSENT-2 enrolled over 16,000 patients to compare tenecteplase and accelerated alteplase 
and found that 30-day mortality was the same in the tenecteplase group and the accelerated 
alteplase at 6.2% each, thereby showing equivalence in outcomes. In fact there was an 
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absolute difference of 0.03% in favour of accelerated alteplase but this was not statistically 
significant (95% CI -0.55% to 0.61%). However, there was a small but statistically significant 
reduction in the incidence of bleeding with tenecteplase of 26.4% compared with 28.9% in 
the accelerated alteplase group. This resulted in fewer blood transfusions in the tenecteplase 
group (4.3% of patients compared with 5.5% in the accelerated alteplase group.  
In summary, with regards to clinical effectiveness and mortality, standard alteplase and 
reteplase are as effective as streptokinase, and tenecteplase is as effective as accelerated 
alteplase.  According to GUSTO-I, accelerated alteplase is believed to be superior to 
streptokinase and if this is the case then indirectly tenecteplase would also be considered to 
be superior to streptokinase (as tenectaplase was superior to accelerated alteplase in 
ASSENT-2). In practice, cost and availability is a significant issue with regards to what is 
ultimately used and also use may also go unchanged for long periods purely because of a 
specific thrombolytic having historical use in a certain area.  
9.6 Other considerations 
In the elderly, evidence suggests that thrombolysis provides a mortality benefit but that 
there is increased risk of adverse events and poor outcomes in those with advancing age. 
The main risk in the older age group is of intracerebral haemorrhage and this is why a clear 
benefit is seen for PPCI in patients above the age of 75 and in fact the benefit is maintained 
even when there are longer door-to-balloon times. Low body weight has also been found to 
be independently associated with increased mortality and morbidity. With regards to sex, it 
is accepted that there is no difference with regards to efficacy but studies have shown that 
for unknown reasons women are less likely to receive any type of reperfusion (thrombolysis 
or PPCI) than men. Anterior infarcts also seem to show an increased benefit with 
thrombolysis over other territories but this may simply reflect the increased baseline risk in 
this group. Overall, when clinicians are deciding who would benefit from thrombolysis it 
appears that patient selection is key and benefits should be balanced against any potential 
risks. 
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